📊 What are ADAP's upcoming earnings dates or product launches that could impact its stock price?

Adaptimmune Therapeutics (ADAP) has several upcoming events that could impact its stock price:

1. **Earnings Report**: ADAP's Q3 2025 earnings report is scheduled for November 5, 2025. The company is expected to report earnings per share (EPS) of -$0.08, with revenue anticipated at $12.5 million.
2. **Product Launch**: The launch of Leticel, Adaptimmune's next-generation T-cell therapy, is expected to occur in 2026. The company is preparing for the launch by expanding its treatment network and enhancing manufacturing capacity.
3. **Clinical Trial Updates**: ADAP is likely to provide updates on its ongoing clinical trials, including the SPEARHEAD-1 trial for TECELRA, which received FDA accelerated approval in 2024. The company may also discuss the progress of its PRAME and CD70 programs.

These events could impact ADAP's stock price due to the following reasons:

1. **Earnings Report**: Positive earnings results could boost investor confidence in the company's financial health and future prospects. Conversely, negative results could lead to a decline in investor confidence and a negative impact on the stock price.
2. **Product Launch**: The anticipated launch of Leticel could positively influence the stock price if investors believe it will lead to increased revenue and market expansion. However, if the launch is met with skepticism or faces regulatory challenges, it could have a negative impact on the stock price.
3. **Clinical Trial Updates**: Positive updates on clinical trials could increase investor optimism about the company's future prospects and drive stock price higher. Conversely, negative updates or setbacks in clinical trials could lead to a decline in investor confidence and a negative impact on the stock price.

Investors should monitor these events closely and consider their potential impact on ADAP's stock price.